Table 1.
Distribution of BSG and SLC16A1 genotypes in multiple myeloma (MM) patients (entire patient cohort and thalidomide-treated patients only) and healthy controls.
| MM Patients (All) | MM Patients (Thalidomide-Treated) | Controls | MM Patients | MM Patients (Thalidomide-Treated) | Controls | ||
|---|---|---|---|---|---|---|---|
|
BSG rs4919859 |
SLC16A1 rs9429505 |
||||||
| CC | 15 (11.2%) | 13 (13.1%) | 19 (14.1%) | AA | 77 (57.0%) | 59 (59.0%) | 67 (49.6%) |
| CG | 65 (48.5%) | 47 (47.5%) | 54 (40.0%) | AG | 51 (37.8%) | 34 (34.0%) | 60 (44.4%) |
| GG | 54 (40.3%) | 39 (39.4%) | 62 (45.9%) | GG | 7 (5.2%) | 7 (7.0%) | 8 (5.9%) |
|
BSG rs4682 |
SLC16A1 rs7169 |
||||||
| CC | 3 (2.2%) | 3 (3.0%) | 4 (3.0%) | CC | 22 (16.3%) | 15 (15.0%) | 23 (17.0%) |
| CT | 45 (33.6%) | 35 (35.4%) | 34 (25.4%) | CT | 63 (46.7%) | 46 (46.0%) | 58 (43.0%) |
| TT | 86 (64.2%) | 61 (61.6%) | 96 (71.6%) | TT | 50 (37.0%) | 39 (39.0%) | 54 (40.0%) |
|
BSG rs8637 |
SLC16A1 rs1049434 |
||||||
| AA | 44 (32.8%) | 32 (32.3%) | 47 (34.8%) | AA | 51 (37.8%) | 39 (39.0%) | 54 (40.0%) |
| AG | 63 (47.0%) | 45 (45.5%) | 61 (45.2%) | AT | 62 (45.9%) | 46 (46.0%) | 58 (43.0%) |
| GG | 27 (20.2%) | 22 (22.2%) | 27 (20.0%) | TT | 22 (16.3%) | 15 (15.0%) | 23 (17.0%) |
|
BSG rs8259 |
SLC16A1 rs7556664 |
||||||
| TT | 77 (57.0%) | 57 (57.0%) | 78 (57.8%) | AA | 50 (37.0%) | 39 (39.0%) | 54 (40.0%) |
| TA | 49 (36.3%) | 35 (35.0%) | 49 (36.3%) | AT | 63 (46.7%) | 46 (46.0%) | 58 (43.0%) |
| AA | 9 (6.7%) | 8 (8.0%) | 8 (5.9%) | TT | 22 (16.3%) | 15 (15.0%) | 23 (17.0%) |
Numbers of patients and controls analysed for various SNPs are slightly different. One person was not included in calculations for rs4919859, rs4682, rs8637 (patients) and rs4682 (controls).